Lungpacer Medical is a medical device company that develops a non-surgical, minimally invasive therapy device to treat diaphragm muscle in critically ill patients who require mechanical ventilation. The company's equipment offers to prevent or reverse muscle-disuse atrophy and maintain diaphragmatic endurance, thus facilitating the weaning by providing a more physiological respiratory pattern and reducing the levels of positive pressure and its harmful effects on the lungs. The Lungpacer Diaphragm Pacing Therapy System™ is the first, minimally invasive, temporary transvenous diaphragmatic neurostimulation system that has FDA Emergency Use Authorization (EUA) for use during the COVID-19 pandemic.